Hepatitis C virus (HCV) is one of the more under-recognised medical comorbidities in schizophrenia. A 2017 meta-analysis by Hughes and colleagues estimated HCV prevalence in serious mental illness at around 8%, compared with about 1% in the general population (Hughes et al., 2016, Lancet Psychiatry). The good news is that hepatitis C is now curable in nearly all cases with 8–12 weeks of well-tolerated oral pills — the era of interferon is over.
Hepatitis C is roughly 8 times more common in serious mental illness than in the general population, mostly because of injection drug use and shared risk environments — and direct-acting antivirals now cure it in 95%+ of cases with a short course of pills.
Why prevalence is higher
Hepatitis C is transmitted primarily through blood-to-blood contact. The major routes:
- Injection drug use — by far the most common in modern populations. People with schizophrenia have higher rates of substance use disorders, including injection drug use; sharing needles or other equipment transmits HCV efficiently.
- Blood transfusion before 1992 — when reliable HCV screening became universal in the US blood supply.
- Tattooing or piercing in unregulated settings.
- Sexual transmission — less efficient than for HIV but possible, especially with traumatic sex or in the context of HIV co-infection.
- Vertical transmission — mother to baby, around 5% per pregnancy without intervention.
Many people with HCV acquired infection decades ago and are unaware. The infection is often asymptomatic for many years until liver disease becomes advanced.
Why it matters
Untreated chronic hepatitis C causes progressive liver fibrosis, cirrhosis, liver cancer, and liver-related death. It is also independently associated with cardiovascular disease, kidney disease, and several cancers. The CDC HCV pages summarise the natural history. In schizophrenia — where multiple competing health risks already shorten life expectancy — adding untreated HCV compounds the burden.
How it is screened
The CDC and US Preventive Services Task Force now recommend universal one-time screening of all adults aged 18–79 for hepatitis C, with repeat screening for those with ongoing risk factors (USPSTF, 2020). Screening is a simple blood test: HCV antibody, with reflex to HCV RNA if antibody is positive. A positive antibody plus detectable RNA means active chronic infection; a positive antibody with undetectable RNA usually means past infection that resolved spontaneously.
People with schizophrenia are screened at lower rates than the general population. Asking your primary-care doctor or psychiatrist about HCV screening — particularly if there is any history of injection drug use, blood transfusion before 1992, or other risk factors — is reasonable.
How treatment works now
Direct-acting antivirals (DAAs) — combinations such as sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) — cure hepatitis C in over 95% of cases with 8–12 weeks of once-daily pills. Side effects are mild (mostly headache and fatigue). The AASLD/IDSA HCV guidance outlines current regimens.
Importantly, treatment works equally well in people with serious mental illness. Older concerns about interferon-based regimens worsening psychiatric symptoms no longer apply — DAAs do not have those effects. Multiple programs now embed HCV treatment directly in mental-health and addiction settings, with cure rates equivalent to the general population.
Drug interactions to watch for
DAAs have well-characterised interactions with several psychiatric medications, particularly carbamazepine, oxcarbazepine, phenytoin, and St John's wort, which can lower DAA levels. The University of Liverpool maintains a free, frequently updated HCV drug interactions database. Pharmacist review before starting DAA therapy is standard practice.
Coverage and cost
DAAs were initially extremely expensive, and many state Medicaid programs imposed restrictions on who could be treated. Most of those restrictions have been lifted in recent years; current US guidelines and most payers now support treatment for essentially everyone with active HCV infection, regardless of fibrosis stage, substance use, or other factors. Cost is rarely a barrier in the US Medicare/Medicaid system today, though prior authorisation may be required.
You develop yellowing of the skin or eyes (jaundice), severe abdominal pain or swelling, dark urine, vomiting blood, confusion, or unexplained bruising — these can be signs of advanced liver disease and need urgent evaluation.
Prevention
- Harm reduction — needle exchange, supervised consumption, and overdose reversal services reduce HCV transmission and connect people with care.
- Buprenorphine and methadone for opioid use disorder reduce injection frequency and are widely available.
- Tattoo and piercing safety — only use licensed practitioners with single-use needles.
- Re-infection after cure is possible if exposure continues, so harm-reduction support is part of long-term care.
The big picture
Hepatitis C in schizophrenia is a story of a problem that has become eminently solvable just as the population most affected by it has been least likely to be screened or treated. Universal screening in adulthood, embedded treatment in mental-health and addiction settings, and harm-reduction support around injection drug use can dramatically reduce HCV burden in this population. Curing HCV is one of the cleaner wins available in serious mental illness care.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.